open access

Vol 68, No 2 (2018)
Short reviews
Get Citation

Should we continue population-based cervical cancer screening programme in Poland? A statement in favour

Andrzej Nowakowski, Maryla Turkot, Kinga Miłosz
DOI: 10.5603/NJO.2018.0017
·
Nowotwory. Journal of Oncology 2018;68(2):108-112.

open access

Vol 68, No 2 (2018)
Short reviews

Abstract

Organised cervical cancer screening programme in Poland introduced in 2006/2007 has never been optimal, largely due to low participation rate. However, recent analysis of trends in the burden of cervical cancer mortality revealed an acceleration of the downward trends in women of the screening age 25–59 around the time of the introduction of the programme. Possible factors responsible for this phenomenon include dissemination of Pap testing (mainly in opportunistic screening) and attempts to assure higher quality of screening procedures, which accompanied the roll-out of the screening programme. Despite the obvious flaws and limitations of the programme, its discontinu­ation might result in adverse epidemiological, clinical and financial outcomes related to limiting the screening to the opportunistic mode only. Therefore the programme requires continuation and improvements. Unfavourable trends in the burden of the disease in older women require rising the upper age limit for screening to facilitate access to screening. Several strategies to raise participation need to be tested. The inevitable advent of more sensitive but less specific, molecular HPV screening requires pilot studies, evaluation of their outcomes and adjustments before full-scale introduction at the national level. According to European Guidelines, this may be executed only within an organised screening programme.

Abstract

Organised cervical cancer screening programme in Poland introduced in 2006/2007 has never been optimal, largely due to low participation rate. However, recent analysis of trends in the burden of cervical cancer mortality revealed an acceleration of the downward trends in women of the screening age 25–59 around the time of the introduction of the programme. Possible factors responsible for this phenomenon include dissemination of Pap testing (mainly in opportunistic screening) and attempts to assure higher quality of screening procedures, which accompanied the roll-out of the screening programme. Despite the obvious flaws and limitations of the programme, its discontinu­ation might result in adverse epidemiological, clinical and financial outcomes related to limiting the screening to the opportunistic mode only. Therefore the programme requires continuation and improvements. Unfavourable trends in the burden of the disease in older women require rising the upper age limit for screening to facilitate access to screening. Several strategies to raise participation need to be tested. The inevitable advent of more sensitive but less specific, molecular HPV screening requires pilot studies, evaluation of their outcomes and adjustments before full-scale introduction at the national level. According to European Guidelines, this may be executed only within an organised screening programme.

Get Citation

Keywords

cervical cancer, screening, organised screening programme, HPV testing, Poland

About this article
Title

Should we continue population-based cervical cancer screening programme in Poland? A statement in favour

Journal

Nowotwory. Journal of Oncology

Issue

Vol 68, No 2 (2018)

Pages

108-112

DOI

10.5603/NJO.2018.0017

Bibliographic record

Nowotwory. Journal of Oncology 2018;68(2):108-112.

Keywords

cervical cancer
screening
organised screening programme
HPV testing
Poland

Authors

Andrzej Nowakowski
Maryla Turkot
Kinga Miłosz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Nowotwory. Journal of Oncology dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl